Issue: February 2019
February 05, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Okogen begins phase 2 trial of adenoviral conjunctivitis treatment
Issue: February 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Okogen has initiated a phase 2 clinical trial to evaluate the safety and efficacy of OKG-0301 for the treatment of acute adenoviral conjunctivitis.
OKG-0301 is a topical ophthalmic formulation of ranpirnase, which is a targeted ribonuclease with broad-spectrum antiviral properties that is found naturally in tears, according to a company press release.
The multicenter, randomized, placebo-controlled, double-masked RUBY trial will evaluate multiple doses of OKG-0301 in 219 adult patients with acute adenoviral conjunctivitis. Researchers will assess the treatment’s ability to reduce viral burden, safety and potential to diminish longer-term complications of adenoviral infection.
Adenoviral conjunctivitis does not have any approved treatments.